Exosomal protein interactors as emerging therapeutic targets in urothelial bladder cancer

Journal of the Egyptian National Cancer Institute

Volumn 27, Issue 2, 2015, Pages 51-58

  Kumari, Nitu ^a   Saxena, Sunita ^a   Agrawal, Usha ^a  

^a SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

Exosome; Urinary bladder cancer

Indexed keywords

ALPHA CATENIN; BETA CATENIN; CTTNBP2 PROTEIN; DDR1 PROTEIN; EXOSOMAL PROTEIN; ITGA4 PROTEIN; MLC1 PROTEIN; MMRN1 PROTEIN; N RAS PROTEIN; NF2 PROTEIN; P21 ACTIVATED KINASE 1; PIK3AR1 PROTEIN; PROTEIN; PROTEIN CDC42; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VSAP PROTEIN; PROTEIN BINDING;

ACTIN FILAMENT; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; CYTOARCHITECTURE; CYTOSKELETON; EXOSOME; FEEDBACK SYSTEM; FOCAL ADHESION; GENE EXPRESSION; HUMAN; METASTASIS; MOLECULAR DOCKING; MOLECULARLY TARGETED THERAPY; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; BIOLOGY; DRUG EFFECTS; METABOLISM; URINARY BLADDER NEOPLASMS;

COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; EXOSOMES; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84929048239     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2015.02.002     Document Type: Article

References (37)

1. Pisitkun T., Shen R.F., Knepper M.A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci 2004, 101:13368-13373.
2. Welton J.L., Khanna S., Giles P.J., Brennan P., Brewis I.A., Staffurth J., et al. Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics 2010, 9:1324-1338.
3. Kellera Sascha, Sandersona Michael P., Stoecka Alexander, Altevogta Peter Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006, 107:102-108.
4. Thery Clotilde Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep 2011, 3:3-15.
5. Dimov Irena, Jankovic Velickovic Ljubinka, Stefanovic Vladisav Urinary exosomes. Sci World J 2009, 9:1107-1118.
6. Caby M.P., Lankar D., Vincendeau-Scherrer C., Raposo G., Bonnerot C. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005, 17:879-887.
7. Admyre C., Johansson S.M., Qazi K.R., Filén J.J., Lahesmaa R., Norman M., et al. Exosomes with immune modulatory features are present in human breast milk. J Immunol 2007, 179:1969-1978.
8. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360:295-305.
9. Bard M.P., Hegmans J.P., Hemmes A., Luider T.M., Willemsen R., Severijnen L.A., et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004, 31:114-121.
10. Asea A., Jean-Pierre C., Kaur P., Rao P., Linhares I.M., Skupski D., et al. Heat shock protein-containing exosomes in midtrimester amniotic fluids. J Reprod Immunol 2008, 79:12-17.
11. Admyre C., Grunewald J., Thyberg J., Gripenbäck S., Tornling G., Eklund A., et al. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur Respir J 2003, 22:578-583.
12. Hosseini-Beheshti Elham, Pham Steven, Adomat Hans, Li Na, Emma S., Tomlinson Guns Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics 2012, 10:863-885.
13. Munoz J.L., Bliss S.A., Greco S.J., Ramkissoon S.H., Ligon K.L., Rameshwar P. Delivery of functional Anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Mol Ther Nucleic Acids 2013, 2:e126.
14. Mathivanan S., Simpson R.J. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics 2009, 9:4997-5000.
15. Anastasiadis A., de Reijke T.M. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012, 4:13-32.
16. Mataka I., Bani-Hani K., Shotar A., Bani Hani O., Bani-Hani I. Transitional cell carcinoma of the urinary bladder: a clinicopathological study. Singapore Med J 2008, 49:790-794.
17. Khatri P., Sellamuthu S., Malhotra P., Amin K., Done A., Draghici S. Recent additions and improvements to the Onto-Tools. Nucleic Acids Res. 2005, 33:762-765.
18. Tarca A.L., Draghici S., Khatri P., et al. A novel signaling pathway impact analysis. Bioinformatics 2009, 25(1):75-82.
19. Lee S.A., Chan C.H., Chen T.C., Yang C.Y., Huang K.C., Tsai C.H., et al. POINeT: protein interactome with sub-network analysis and hub prioritization. BMC Bioinformatics 2009, 15:1471-2105.
20. De Las Rivas J., Fontanillo C. Protein-protein interaction networks: unraveling the wiring of molecular machines within the cell. Brief Funct Genomics 2012, 11:489-496.
21. Smoot M.E., Ono K., Ruscheinski J., Wang P.L., Ideker T.M.E. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27:431-432.
22. Barabási A.L., Oltvai Z.N. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004, 5:101-113.
23. Lin C.Y., Chin C.H., Wu H.H., Chen S.H., Ho C.W., Ko M.T. Hubba: hub objects analyzer a framework of interactome hubs identification for network biology. Nucleic Acids Res 2008, 36:438-443.
24. Henderson M.C., Azorsa D.O. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol 2012, 2:38.
25. Keller S., Sanderson M.P., Stoeck A., Altevogt P. Exosomes: from biogenesis and secretion to biological function. Immunol Lett 2006, 107:102-108.
26. Inge L.J., Rajasekaran S.A., Wolle D., Barwe S.P., Ryazantsev S., Ewing C.M., et al. Alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. Mol Cancer Ther 2008, 7:1386-1397.
27. Meng W., Takeichi M. Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol 2009, 1:a002899.
28. Yonemura S., Itoh M., Nagafuchi A. Cell-to-cell adherens junction formation and actin filament organization: similarities and differences between non-polarized fibroblasts and polarized epithelial cells. J Cell Sci 1995, 108:127-142.
29. Bosman F.T., Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003, 200:423-428.
30. LExosomes: secreted vesicles and intercellular communicationsiotta L A, Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986;46:1-7.
31. Chairoungdua A., Smith D.L., Pochard P., Hull M., Caplan M.J. Exosome release of b-catenin: a novel mechanism that antagonizes Wnt signaling. JCB 2010, 190:1079-1091.
32. Benninger Y., Thurnherr T., Pereira J.A., Krause S., Wu X., Chrostek-Grashoff A., et al. Essential and distinct roles for cdc42 and rac1 in the regulation of Schwann cell biology during peripheral nervous system development. JBC 2007, 177:1051-1061.
33. Francis J.C., Thomsen M.K., Taketo M.M., Swain A. β-Catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genet 2013, 9:e1003180.
34. Klose A., Ahmadian M.R., Schuelke M., Scheffzek K., Hoffmeyer S., Gewies A., et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1 (NF1). Hum Mol Genet 2010, 7:1261-1268.
35. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
36. Cohen M.H., Gootenberg J., Keegan P., Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007, 12:713-718.
37. Ferrara N., Hillan K.J., Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005, 333:328-335.